Clinical trial · Interventional
Epoetin Alfa for Anemia in Patients With Cancer Receiving Non-platinum Chemotherapy
Double-Blind, Placebo-Controlled Study to Assess the Effect of Early Intervention and/or Treatment With Epoetin Alfa on Anemia in Cancer Patients Receiving Non-Platinum-Containing Chemotherapy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate the effectiveness of epoetin alfa versus placebo in reducing or preventing the need for transfusions in anemic patients with non-myeloid cancer on non-platinum chemotherapy, and to investigate quality-of-life benefits associated with the use of epoetin alfa. Epoetin alfa is a genetically engineered protein that stimulates red blood cell production.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Anemia | — | UNRESOLVED | — |
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Neoplasm | Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Epoetin alfa | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Proportion of patients transfused after one month
Secondary outcomes (1)
- measure
- Changes in hemoglobin, hematocrit, and developing red blood cells from the start of the study until study completion; Changes in quality-of-life; Safety
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Confirmed diagnosis of non-myeloid malignancy * undergoing treatment with non-platinum-containing chemotherapy, or non-platinum-containing chemotherapy is imminent * Eastern Cooperative Oncology Group (which is a scale used by researchers to represent the level of activity that a patient is capable of) score of 0 (fully active, no disease restriction) to 3 (capable of only limited self-care, confined to bed or chair more than 50% of waking hours) * life expectancy of at least 6 months * baseline hemoglobin \<= 10.5 grams per deciliter (or a fall in hemoglobin level \>= 1.5 grams per deciliter per cycle or per month since the beginning of the current course of chemotherapy such that it dropped to \<= 12 grams per deciliter) and baseline count of \<125,000 microliters for developing red cells Exclusion Criteria: * Patients having a clinically significant disease other than cancer * treated by platinum-containing chemotherapy within 3 months of study start * having uncontrolled high blood pressure, a history of seizure, or untreated iron, folate, or Vitamin B12 deficiency * received a transfusion or radiotherapy within 2 weeks of study start, or had surgery within 1 week of study start * intending to use steroid drugs during the study
References
Publications (0)
Data not yet available